CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients — Stella

Home/Kidney Transplant; Complications/

View on ClinicalTrials.gov

Recruiting

Back to Kidney Transplant; Complications trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Minnesota, Minneapolis, Minnesota

Key details

Phase

Early testing / Safety & dosing

Sponsor

University of Minnesota

Enrollment target

~30 participants

Started

October 2025

Primary completion

August 2027

Age range

18 Years – 70 Years

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.